TLR2_GORGO
ID TLR2_GORGO Reviewed; 784 AA.
AC B3Y615;
DT 10-FEB-2009, integrated into UniProtKB/Swiss-Prot.
DT 23-SEP-2008, sequence version 1.
DT 03-AUG-2022, entry version 78.
DE RecName: Full=Toll-like receptor 2;
DE AltName: CD_antigen=CD282;
DE Flags: Precursor;
GN Name=TLR2;
OS Gorilla gorilla gorilla (Western lowland gorilla).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Gorilla.
OX NCBI_TaxID=9595;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RA Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T., Kimura A.;
RT "Molecular evolution of the Toll-like receptor-related genes in primates.";
RL Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases.
CC -!- FUNCTION: Cooperates with LY96 to mediate the innate immune response to
CC bacterial lipoproteins and other microbial cell wall components.
CC Cooperates with TLR1 or TLR6 to mediate the innate immune response to
CC bacterial lipoproteins or lipopeptides. Acts via MYD88 and TRAF6,
CC leading to NF-kappa-B activation, cytokine secretion and the
CC inflammatory response (By similarity). May also promote apoptosis in
CC response to lipoproteins. Forms activation clusters composed of several
CC receptors depending on the ligand, these clusters trigger signaling
CC from the cell surface and subsequently are targeted to the Golgi in a
CC lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in
CC response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to
CC triacylated lipopeptides (By similarity).
CC {ECO:0000250|UniProtKB:O60603, ECO:0000250|UniProtKB:Q9QUN7}.
CC -!- SUBUNIT: Interacts with LY96, TLR1 and TLR6 (via extracellular domain).
CC TLR2 seems to exist in heterodimers with either TLR1 or TLR6 before
CC stimulation by the ligand. The heterodimers form bigger oligomers in
CC response to their corresponding ligands as well as further heterotypic
CC associations with other receptors such as CD14 and/or CD36. Binds MYD88
CC (via TIR domain). Interacts with TICAM1. Interacts with CNPY3.
CC Interacts with ATG16L1. Interacts with PPP1R11. Interacts with TICAM2.
CC {ECO:0000250|UniProtKB:O60603, ECO:0000250|UniProtKB:Q9QUN7}.
CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250|UniProtKB:Q9QUN7}; Single-
CC pass type I membrane protein {ECO:0000255}. Cytoplasmic vesicle,
CC phagosome membrane {ECO:0000250|UniProtKB:Q9QUN7}; Single-pass type I
CC membrane protein {ECO:0000255}. Membrane raft
CC {ECO:0000250|UniProtKB:O60603}. Note=Does not reside in lipid rafts
CC before stimulation but accumulates increasingly in the raft upon the
CC presence of the microbial ligand. In response to diacylated
CC lipoproteins, TLR2:TLR6 heterodimers are recruited in lipid rafts, this
CC recruitment determine the intracellular targeting to the Golgi
CC apparatus. Triacylated lipoproteins induce the same mechanism for
CC TLR2:TLR1 heterodimers. {ECO:0000250|UniProtKB:O60603}.
CC -!- DOMAIN: Ester-bound lipid substrates are bound through a crevice formed
CC between the LRR 11 and LRR 12. {ECO:0000250}.
CC -!- DOMAIN: The ATG16L1-binding motif mediates interaction with ATG16L1.
CC {ECO:0000250}.
CC -!- PTM: Ubiquitinated at Lys-754 by PPP1R11, leading to its degradation.
CC Deubiquitinated by USP2. {ECO:0000250|UniProtKB:Q9QUN7}.
CC -!- PTM: Glycosylation of Asn-442 is critical for secretion of the N-
CC terminal ectodomain of TLR2. {ECO:0000250|UniProtKB:O60603}.
CC -!- SIMILARITY: Belongs to the Toll-like receptor family. {ECO:0000305}.
CC -!- CAUTION: In some plant proteins and in human SARM1, the TIR domain has
CC NAD(+) hydrolase (NADase) activity (By similarity). However, despite
CC the presence of the catalytic Asp residue, the isolated TIR domain of
CC human TLR4 lacks NADase activity (By similarity). Based on this, it is
CC unlikely that Toll-like receptors have NADase activity.
CC {ECO:0000250|UniProtKB:O00206, ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AB445627; BAG55024.1; -; mRNA.
DR RefSeq; NP_001266693.1; NM_001279764.1.
DR RefSeq; XP_018880449.1; XM_019024904.1.
DR RefSeq; XP_018880450.1; XM_019024905.1.
DR RefSeq; XP_018880451.1; XM_019024906.1.
DR RefSeq; XP_018880452.1; XM_019024907.1.
DR RefSeq; XP_018880453.1; XM_019024908.1.
DR RefSeq; XP_018880454.1; XM_019024909.1.
DR RefSeq; XP_018880455.1; XM_019024910.1.
DR RefSeq; XP_018880456.1; XM_019024911.1.
DR RefSeq; XP_018880457.1; XM_019024912.1.
DR AlphaFoldDB; B3Y615; -.
DR SMR; B3Y615; -.
DR STRING; 9593.ENSGGOP00000003012; -.
DR Ensembl; ENSGGOT00000003080; ENSGGOP00000003012; ENSGGOG00000003066.
DR GeneID; 101128447; -.
DR KEGG; ggo:101128447; -.
DR CTD; 7097; -.
DR eggNOG; KOG4641; Eukaryota.
DR GeneTree; ENSGT00940000156323; -.
DR InParanoid; B3Y615; -.
DR OrthoDB; 282372at2759; -.
DR Proteomes; UP000001519; Chromosome 4.
DR Bgee; ENSGGOG00000003066; Expressed in liver and 6 other tissues.
DR GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR GO; GO:0030670; C:phagocytic vesicle membrane; IEA:UniProtKB-SubCell.
DR GO; GO:0035354; C:Toll-like receptor 1-Toll-like receptor 2 protein complex; IEA:Ensembl.
DR GO; GO:0035355; C:Toll-like receptor 2-Toll-like receptor 6 protein complex; IEA:Ensembl.
DR GO; GO:0001540; F:amyloid-beta binding; IEA:Ensembl.
DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR GO; GO:0001530; F:lipopolysaccharide binding; IEA:Ensembl.
DR GO; GO:0050135; F:NAD(P)+ nucleosidase activity; IEA:UniProtKB-EC.
DR GO; GO:0061809; F:NAD+ nucleotidase, cyclic ADP-ribose generating; IEA:UniProtKB-EC.
DR GO; GO:0038187; F:pattern recognition receptor activity; IEA:Ensembl.
DR GO; GO:0042834; F:peptidoglycan binding; IEA:Ensembl.
DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central.
DR GO; GO:0035325; F:Toll-like receptor binding; IEA:Ensembl.
DR GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR GO; GO:0042497; F:triacyl lipopeptide binding; IBA:GO_Central.
DR GO; GO:0001775; P:cell activation; IEA:Ensembl.
DR GO; GO:0071726; P:cellular response to diacyl bacterial lipopeptide; ISS:UniProtKB.
DR GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR GO; GO:0071223; P:cellular response to lipoteichoic acid; IEA:Ensembl.
DR GO; GO:0071727; P:cellular response to triacyl bacterial lipopeptide; ISS:UniProtKB.
DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR GO; GO:0051607; P:defense response to virus; IEA:Ensembl.
DR GO; GO:0042496; P:detection of diacyl bacterial lipopeptide; IEA:Ensembl.
DR GO; GO:0042495; P:detection of triacyl bacterial lipopeptide; IEA:Ensembl.
DR GO; GO:0007252; P:I-kappaB phosphorylation; IEA:Ensembl.
DR GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; IEA:InterPro.
DR GO; GO:1903974; P:positive regulation of cellular response to macrophage colony-stimulating factor stimulus; IEA:Ensembl.
DR GO; GO:0032722; P:positive regulation of chemokine production; IEA:Ensembl.
DR GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR GO; GO:0032757; P:positive regulation of interleukin-8 production; IEA:Ensembl.
DR GO; GO:1904466; P:positive regulation of matrix metallopeptidase secretion; IEA:Ensembl.
DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IEA:Ensembl.
DR GO; GO:0034123; P:positive regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IEA:Ensembl.
DR GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IEA:InterPro.
DR GO; GO:0002224; P:toll-like receptor signaling pathway; IBA:GO_Central.
DR GO; GO:0038124; P:toll-like receptor TLR6:TLR2 signaling pathway; IEA:Ensembl.
DR Gene3D; 3.40.50.10140; -; 1.
DR Gene3D; 3.80.10.10; -; 1.
DR InterPro; IPR000483; Cys-rich_flank_reg_C.
DR InterPro; IPR001611; Leu-rich_rpt.
DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR InterPro; IPR032675; LRR_dom_sf.
DR InterPro; IPR000157; TIR_dom.
DR InterPro; IPR027185; TLR2.
DR InterPro; IPR017241; Toll-like_receptor.
DR InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR PANTHER; PTHR24365; PTHR24365; 1.
DR PANTHER; PTHR24365:SF17; PTHR24365:SF17; 1.
DR Pfam; PF13855; LRR_8; 2.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01582; TIR; 1.
DR PIRSF; PIRSF037595; Toll-like_receptor; 1.
DR SMART; SM00369; LRR_TYP; 7.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00255; TIR; 1.
DR SUPFAM; SSF52200; SSF52200; 1.
DR PROSITE; PS51450; LRR; 11.
DR PROSITE; PS50104; TIR; 1.
PE 2: Evidence at transcript level;
KW Cytoplasmic vesicle; Disulfide bond; Glycoprotein; Immunity;
KW Inflammatory response; Innate immunity; Isopeptide bond;
KW Leucine-rich repeat; Membrane; NAD; Receptor; Reference proteome; Repeat;
KW Signal; Transmembrane; Transmembrane helix; Ubl conjugation.
FT SIGNAL 1..20
FT /evidence="ECO:0000255"
FT CHAIN 21..784
FT /note="Toll-like receptor 2"
FT /id="PRO_0000363774"
FT TOPO_DOM 21..587
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT TRANSMEM 588..608
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 609..784
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT REPEAT 54..77
FT /note="LRR 1"
FT REPEAT 78..101
FT /note="LRR 2"
FT REPEAT 102..125
FT /note="LRR 3"
FT REPEAT 126..150
FT /note="LRR 4"
FT REPEAT 151..175
FT /note="LRR 5"
FT REPEAT 176..199
FT /note="LRR 6"
FT REPEAT 200..223
FT /note="LRR 7"
FT REPEAT 224..250
FT /note="LRR 8"
FT REPEAT 251..278
FT /note="LRR 9"
FT REPEAT 279..308
FT /note="LRR 10"
FT REPEAT 309..337
FT /note="LRR 11"
FT REPEAT 338..361
FT /note="LRR 12"
FT REPEAT 362..388
FT /note="LRR 13"
FT REPEAT 389..414
FT /note="LRR 14"
FT REPEAT 415..437
FT /note="LRR 15"
FT REPEAT 438..457
FT /note="LRR 16"
FT REPEAT 458..478
FT /note="LRR 17"
FT REPEAT 479..500
FT /note="LRR 18"
FT REPEAT 501..524
FT /note="LRR 19"
FT DOMAIN 525..579
FT /note="LRRCT"
FT DOMAIN 639..782
FT /note="TIR"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT MOTIF 761..778
FT /note="ATG16L1-binding motif"
FT SITE 349
FT /note="Interaction with bacterial lipopeptide"
FT /evidence="ECO:0000250"
FT CARBOHYD 114
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 199
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 414
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 442
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT DISULFID 30..36
FT /evidence="ECO:0000250"
FT DISULFID 353..382
FT /evidence="ECO:0000250"
FT DISULFID 432..454
FT /evidence="ECO:0000250"
FT CROSSLNK 754
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in ubiquitin)"
FT /evidence="ECO:0000250|UniProtKB:O60603"
SQ SEQUENCE 784 AA; 89824 MW; 1465031E6825069C CRC64;
MPHTLWMVWV LGVIISLSKE ESSNQASLSC DRNGICKGSS GSLNSIPSGL TEAVKSLDLS
NNRITYISNS DLQRCVNLQA LVLTSNGINT IEEDSFSSLG SLEHLDLSYN YLSNLSSSWF
KPLSSLTFLN LLGNPYKTLG ETSLFSHLTK LQILRVGNMD TFTKIQRKDF AGLTFLEELE
IDASDLQSYE PKSLKSIQNV SHLILHMKQH ILLLEIFVDV TSSVECLELR DTDLDTFHFS
ELSTGETNSL IKKFTFRNVK ITDESLFQVM KLLNQISGLL ELEFDDCTLN GVGNFRASDN
DRVIDPGKVE TLTIRRLHIP RFYLFYDLST LYSLTERVKR ITVENSKVFL VPCLLSQHLK
SLEYLDLSEN LMVEEYLKNS ACEDAWPSLQ TLILRQNHLA SLEKTGETLL TLKNLTNVDI
SKNSFHSMPE TCQWPEKMKY LNLSSTRIHS VTGCIPKTLE ILDVSNNNLN LFSLNLPQLK
ELYISRNKLM TLPDASLLPM LLVLKISRNA ITTFSKEQLD SFHTLKTLEA GGNNFICSCE
FLSFTQEQQA LAKVLIDWPA NYLCDSPSHV RGQQVQDVRL SVSECHRTAL VSGMCCALFL
LILLTGVLCH RFHGLWYMKM MWAWLQAKRK PRKAPSRNIC YDAFVSYSER DAYWVENLMV
QELENFNPPF KLCLHKRDFI PGKWIIDNII DSIEKSHKTV FVLSENFVKS EWCKYELDFS
HFRLFDENND AAILILLEPI EKKAIPQRFC KLRKIMNTKT YLEWPMDEAQ REGFWVNLRA
AIKS
